Reviewing Syros Pharmaceuticals (SYRS) and Baxalta (BXLT)

Syros Pharmaceuticals (NASDAQ: SYRS) and Baxalta (NYSE:BXLT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Dividends

Baxalta pays an annual dividend of $0.28 per share. Syros Pharmaceuticals does not pay a dividend. Baxalta pays out 23.5% of its earnings in the form of a dividend. Syros Pharmaceuticals has increased its dividend for 2 consecutive years.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Syros Pharmaceuticals and Baxalta, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syros Pharmaceuticals 0 2 6 0 2.75
Baxalta 0 0 0 0 N/A

Syros Pharmaceuticals currently has a consensus price target of $23.83, suggesting a potential upside of 143.95%.

Earnings & Valuation

This table compares Syros Pharmaceuticals and Baxalta’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Syros Pharmaceuticals $320,000.00 802.97 -$47.74 million ($1.74) -5.61
Baxalta N/A N/A N/A $1.19 N/A

Baxalta has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Baxalta, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Syros Pharmaceuticals and Baxalta’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Syros Pharmaceuticals N/A -62.01% -55.65%
Baxalta 9.37% 14.28% 4.62%

Insider and Institutional Ownership

58.0% of Syros Pharmaceuticals shares are owned by institutional investors. 33.6% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Syros Pharmaceuticals beats Baxalta on 6 of the 11 factors compared between the two stocks.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

About Baxalta

Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit